Note 9 - Related Party Note Payable	9 Months Ended
Sep. 30, 2020
Notes to Financial Statements
Related Party Notes Payable [Text Block]	NOTE 9. RELATED PARTY NOTE PAYABLE On February 27, 2019, the Company issued a $1.0 million promissory note payable to Pioneer Pharma (Hong Kong) Company Ltd. (“Pioneer Pharma”), which was amended on June 25, 2019 and May 14, 2020 ( the “Promissory Note”). The Promissory Note provided for an interest payment of $150 thousand which was initially amended to a payment of $300 thousand and subsequently to the delivery of 65,178 units of NeutroPhase ( 40ml ) to Pioneer Pharma, inclusive of 40,644 units previously delivered in the first quarter of 2020. The second amendment to the Promissory Note also provided the Company with the right to repay the note at any time. On May 14, 2020, the Company repaid the $1.0 million principal balance of the Promissory Note using proceeds raised through the ATM program (see Note 12, “Stockholders' Equity (Deficit)”). As of September 30, 2020, the remaining interest payable was $104 thousand, which was settled through the delivery of 24,534 units of NeutroPhase subsequent to September 30, 2020 in October 2020. Upon full repayment of principal and interest during the fourth quarter of 2020, the Company was released from the Promissory Note with Pioneer Pharma. In connection with the Promissory Note, the Company paid China Kington a 2% fee for brokering the transaction and entered into a consulting agreement with China Kington for a term of one year, which expired on March 1, 2020. Bob Wu, acting in a dual role as a member of the Company's Board of Directors and as principal of China Kington, was paid $100 thousand pursuant to such consulting agreement. Upon the expiration of the original consulting agreement, the parties entered into a consulting agreement, in which no cash compensation will be paid. Debt issuance costs associated with the issuance of the Promissory Note of $20 thousand was recognized and recorded as an offset to the related party note payable in the condensed consolidated balance sheet. The interest expense recognized, including amortization of the issuance costs, was $0 and $75 thousand during the three and nine months ended September 30, 2020, respectively. The interest expense recognized, including amortization of the issuance costs, was $45 thousand and $175 thousand during the three and nine months ended September 30, 2019, respectively.

NOTE

RELATED PARTY NOTE PAYABLE

February 27, 2019,

the Company issued a

$1.0

million promissory note payable to Pioneer Pharma (Hong Kong) Company Ltd. (“Pioneer Pharma”), which was amended on

June 25, 2019

and

May 14, 2020 (

the “Promissory Note”). The Promissory Note provided for an interest payment of

$150

thousand which was initially amended to a payment of

$300

thousand and subsequently to the delivery of

65,178

units of NeutroPhase (

40ml

) to Pioneer Pharma, inclusive of

40,644

units previously delivered in the

first

quarter of

2020.

The

second

amendment to the Promissory Note also provided the Company with the right to repay the note at any time. On

May 14, 2020,

the Company repaid the

$1.0

million principal balance of the Promissory Note using proceeds raised through the ATM program (see Note

12,

“Stockholders' Equity (Deficit)”). As of

September 30, 2020,

the remaining interest payable was

$104

thousand, which was settled through the delivery of

24,534

units of NeutroPhase subsequent to

September 30, 2020

October 2020.

Upon full repayment of principal and interest during the

fourth

quarter of

2020,

the Company was released from the Promissory Note with Pioneer Pharma.

In connection with the Promissory Note, the Company

paid China Kington a

fee for brokering the transaction and entered into a consulting agreement with China Kington for a term of

one

year, which expired on

March 1, 2020.

Bob Wu, acting in a dual role as a member of the Company's Board of Directors and as principal of China Kington, was paid

$100

thousand pursuant to such consulting agreement. Upon the expiration of the original consulting agreement, the parties entered into a consulting agreement, in which

cash compensation will be paid. Debt issuance costs associated with the issuance of the Promissory Note of

$20

thousand was recognized and recorded as an offset to the related party note payable in the condensed consolidated balance sheet.

The interest expense recognized, including amortization of the issuance costs, was

and

$75

thousand during the

three

and

nine

months ended

September 30, 2020,

respectively. The interest expense recognized, including amortization of the issuance costs, was

$45

thousand and

$175

thousand during the

three

and

nine

months ended

September 30, 2019,

respectively.